⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28069898 | 0.82 | — | — | |
| SCHEMBL456572 | 0.78 | — | — | |
| SCHEMBL28142011 | 0.77 | KCNQ3 (0.30) | — | |
| SCHEMBL523704 | 0.74 | — | — | |
| SCHEMBL900438 | 0.74 | PDE2A (0.34) | — | |
| SCHEMBL1355970 | 0.73 | — | — | |
| SCHEMBL457212 | 0.73 | — | — | |
| SCHEMBL443199 | 0.73 | — | — | |
| SCHEMBL3885195 | 0.72 | AR (0.33) | — | |
| SCHEMBL6689007 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. | 2020-09-15 | — | — | US | claimed |
| US-10272072-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2019-04-30 | — | — | US | claimed |
| US-20170368039-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA TM, LLC (US) | 2017-12-28 | — | — | US | claimed |
| US-20140294805-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO EARLY DISCOVERY, INC. | 2014-10-02 | — | — | US | claimed |
| EP-2611804-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Forma TM, LLC. (US) | 2013-07-10 | — | — | EP | claimed |
| WO-2012031197-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | claimed |
| WO-2010103429-A1 | 1,1-(Dimethyl-Ethylamino)-2-Hydroxy-Propoxy]-Ethyl}-3-Methyl-Biphenyl-4- Carboxylic Acid Derivatives As Calcium Receptor Antagonists | PFIZER INC. (US) | 2010-09-16 | — | — | WO | claimed |
| US-7371747-B2 | Cyanoalkylamino derivatives as protease inhibitors | MERCK FROSST CANADA & CO. (CA) | 2008-05-13 | — | — | US | claimed |
| EP-1446115-B1 | CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2008-02-27 | — | — | EP | claimed |
| EP-1446115-A4 | CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS | MERCK FROSST CANADA INC (CA) | 2005-02-02 | — | — | EP | claimed |
| US-20050014941-A1 | Cyanoalkylamino derivatives as protease inhibitors | MERCK FROSST CANADA LTD. (CA) | 2005-01-20 | — | — | US | claimed |
| EP-1446115-A2 | CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS | Merck Frosst Canada & Co. (CA) | 2004-08-18 | — | — | EP | claimed |
| WO-2003041649-A2 | CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-05-22 | — | — | WO | claimed |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| CN-109415359-B | Heterocyclic GPR119 agonist compounds | 人类制药有限公司 | 2022-03-04 | — | — | CN | disclosed |
| EP-0529395-A2 | Benzamide multidrug resistance reversing agents | Bristol-Myers Squibb Company (US) | 1993-03-03 | — | — | EP | disclosed |
| US-5173486-A | Adjuvant chemotherapy for cancer and tumor therapy | BRISTOL-MYERS SQUIBB COMPANY (US) | 1992-12-22 | — | — | US | disclosed |
| US-5162521-A | Processes for making cephems from allenylazetidinone derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 1992-11-10 | — | — | US | disclosed |
| US-5162524-A | Antibiotics | BRISTOL-MYERS SQUIBB COMPANY (US) | 1992-11-10 | — | — | US | disclosed |